{
    "clinical_study": {
        "@rank": "164911", 
        "arm_group": [
            {
                "arm_group_label": "combination with Erlotinib", 
                "arm_group_type": "Experimental", 
                "description": "Erlotinib 150mg qd combination with docetaxel 75mg/m2 or pemetrexed 500mg/m2"
            }, 
            {
                "arm_group_label": "sequential chemotherapy for Erlotinib", 
                "arm_group_type": "Active Comparator", 
                "description": "docetaxel 75mg/m2 or pemetrexed 500mg/m2\uff0cafter PD\uff0cErlotinib 150mg qd"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate and compare safety and effectiveness of\n      Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients\n      With EGFR - TKI Resistance of EGFR Mutations"
        }, 
        "brief_title": "Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLC", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Non Small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "from the first cycle of treatment (day one) to two month after the last cycle"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Sign the informed consent\n\n          2. \u226518 years\n\n          3. According to RECIST 1.1 standard, at least one measurable lesions\n\n          4. Histology and cytology confirmed with unfavorable surgical locally advanced stage\n             (stage IIIB) or metastatic NSCLC (IV), Sensitive EGFR gene mutation\n\n          5. Palliative treatment has received two medicine first-line platinum-based chemotherapy\n             and EGFR - TKI second-line treatment and objective clinical benefit (CR, PR or SD is\n             more than 6 months), RESIST standard curative effect evaluation for progress\n\n          6. PS=0,1,2\n\n          7. No serious blood, heart, lung, liver and kidney dysfunction, and immune deficiency\n\n          8. Hb\u22659g/dL\uff1bWBC\u22653*109/L\uff0cANC\u22651.5*109/L\uff0cPLT\u226575*109/L\n\n          9. Men or women of childbearing age in the experiment are willing to take contraceptive\n             measures\n\n         10. Estimated survival period for 3 months or more\n\n        Exclusion Criteria:\n\n          1. The palliative chemotherapy ever use docetaxel and pemetrexed\n\n          2. small cell lung cancer non small cell hybrid\n\n          3. Women during pregnancy or lactation\n\n          4. In the past the anti-tumor treatment of any outstanding ease of > CTCAE 2 levels of\n             toxicity\n\n          5. Ccr<30 ml/min (calculated by Cockcroft-Gault formula)\n\n          6. hepatic insufficiency\uff1a Tbil> 1.5\u00d7ULN ALT and AST > 2.5\u00d7ULN (Patients with liver\n             metastasis>5\u00d7ULN) Alkaline phosphatase\uff1e2.5 \u00d7ULN(Patients with liver metastasis>5\u00d7ULN)\n\n          7. Severe symptomatic heart disease\n\n          8. Symptomatic brain metastases\n\n          9. In the last 5 years have been or are suffering from other histological types of\n             malignant tumor\n\n         10. There are serious or uncontrolled systemic diseases\n\n         11. During the study period planned radiotherapy on target lesion\n\n         12. During the study period, plans to use other antineoplastic therapy\n\n         13. Clinical study on treatment of 30 days beginning period prior to participate in any\n             study drug"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02037997", 
            "org_study_id": "CJH-Erlotinib-2013"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "combination with Erlotinib", 
                    "sequential chemotherapy for Erlotinib"
                ], 
                "description": "docetaxel 75mg/m2  ivgtt D1", 
                "intervention_name": "docetaxel", 
                "intervention_type": "Drug", 
                "other_name": "docetaxel"
            }, 
            {
                "arm_group_label": [
                    "combination with Erlotinib", 
                    "sequential chemotherapy for Erlotinib"
                ], 
                "description": "pemetrexed 500mg/m2 ivgtt D1", 
                "intervention_name": "pemetrexed", 
                "intervention_type": "Drug", 
                "other_name": "pemetrexed"
            }, 
            {
                "arm_group_label": [
                    "combination with Erlotinib", 
                    "sequential chemotherapy for Erlotinib"
                ], 
                "description": "Erlotinib 150mg qd", 
                "intervention_name": "Erlotinib", 
                "intervention_type": "Drug", 
                "other_name": "Erlotinib"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Docetaxel", 
                "Pemetrexed", 
                "Erlotinib"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "PFS", 
        "lastchanged_date": "January 15, 2014", 
        "location": {
            "contact": {
                "email": "changjianhua@163.com", 
                "last_name": "Chang J hua, PD", 
                "phone": "13916619284"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200032"
                }, 
                "name": "Cancer hospital Fudan University"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Chemotherapy in Combination With Erlotinib, or Sequential Chemotherapy for Erlotinib for Treatment, EGFR - TKI Resistance of EGFR Mutations in Patients With NSCLC Randomized Controlled Phase II Clinical Study", 
        "overall_contact": {
            "email": "changjianhua@163.com", 
            "last_name": "Chang J hua, PD", 
            "phone": "13916619284"
        }, 
        "overall_official": {
            "affiliation": "Fudan University", 
            "last_name": "Chang J hua, PD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression-free survival (PFS)", 
            "safety_issue": "Yes", 
            "time_frame": "from the first cycle of treatment (day one) to two month after the last cycle"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02037997"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fudan University", 
            "investigator_full_name": "Chang Jian Hua", 
            "investigator_title": "attending", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Fudan University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fudan University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}